<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159936" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Eletriptan</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Norteman</surname>
            <given-names>Kimberly</given-names>
          </name>
          <aff>University of Illinois College of Medicine Peoria</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Awosika</surname>
            <given-names>Ayoola O.</given-names>
          </name>
          <aff>University of Illinois College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kimberly Norteman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayoola Awosika declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159936.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Eletriptan is a medication approved by the U.S. Food and Drug Administration (FDA) to treat acute migraine headaches in adults, with or without aura.&#x000a0;Eletriptan was discovered&#x000a0;during research on serotonin receptors&#x02014;the neurotransmitter associated with migraine pathophysiology.<xref ref-type="bibr" rid="article-159936.r1">[1]</xref>&#x000a0;Serotonin can induce vasoconstriction of cranial blood vessels, thereby alleviating migraine pain.<xref ref-type="bibr" rid="article-159936.r1">[1]</xref>&#x000a0;However, serotonin can also cause adverse effects by affecting different receptors. Eletriptan demonstrated notable affinity and selectivity for the 5-HT(1B/1D/1F) receptors involved in migraines.<xref ref-type="bibr" rid="article-159936.r2">[2]</xref>&#x000a0;This drug belongs to a class of medications commonly known as 'triptans,' which are serotonin receptor agonists.<xref ref-type="bibr" rid="article-159936.r3">[3]</xref></p>
        <p>Currently, there is insufficient significant data advocating for the use of eletriptan in the treatment of pediatric migraine headaches despite the utilization of other triptans for this purpose.<xref ref-type="bibr" rid="article-159936.r4">[4]</xref>&#x000a0;Eletriptan was evaluated in several randomized controlled trials involving patients with moderate-to-severe migraines, with or without aura. The primary endpoint measured was the pain-free response 2 hours after taking the medication. The secondary endpoints included pain relief, sustained pain-free response, recurrence rate, use of rescue medication, and adverse events. The results revealed that eletriptan exhibited superiority over placebo and demonstrated comparable or superior efficacy and tolerability to other triptans.<xref ref-type="bibr" rid="article-159936.r5">[5]</xref></p>
        <p>Several trials also explored the effects of eletriptan on migraine pain of varying intensities, comparing mild versus moderate-to-severe pain. The findings indicated that early intervention with eletriptan during mild pain yielded better outcomes than delaying treatment until the pain escalated to moderate-to-severe levels.<xref ref-type="bibr" rid="article-159936.r6">[6]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Eletriptan received approval from the FDA in December 2002 for treating acute migraines in adults, both with and without aura.<xref ref-type="bibr" rid="article-159936.r7">[7]</xref>&#x000a0;The approval was based on the data from the clinical trials that indicated the safety and efficacy of eletriptan in various doses and conditions.<xref ref-type="bibr" rid="article-159936.r8">[8]</xref>&#x000a0;The American Headache Society (AHS) advocates for the use of triptans, including eletriptan, as an A-level recommendation for the acute treatment of migraines in adults.<xref ref-type="bibr" rid="article-159936.r9">[9]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Research has indicated a potential off-label application of eletriptan in the short-term prophylaxis of cluster headaches in adults. However, additional studies are required to validate these findings.<xref ref-type="bibr" rid="article-159936.r10">[10]</xref>&#x000a0;Currently, other triptans, such as sumatriptan, have FDA approval for the acute treatment of cluster headaches.<xref ref-type="bibr" rid="article-159936.r11">[11]</xref></p>
      </sec>
      <sec id="article-159936.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Eletriptan belongs to the class of organic compounds known as indoles, specifically a methylpyrrolidinyltryptamine substituted with a benzene sulfonyl derivative. In understanding the pathophysiology of migraines, various neurotransmitters, neuropeptides, and neurochemical systems contribute to the pain associated with this condition. The 3 primary components of migraine pathophysiology include vasodilation, particularly of the cerebral and meningeal arteries, neurogenic inflammation, and activation of the trigeminovascular system.<xref ref-type="bibr" rid="article-159936.r12">[12]</xref><xref ref-type="bibr" rid="article-159936.r13">[13]</xref><xref ref-type="bibr" rid="article-159936.r14">[14]</xref>&#x000a0;</p>
        <p>Eletriptan exerts its potency as a serotonin receptor agonist, specifically targeting the 5-HT(1B/1D) receptor.<xref ref-type="bibr" rid="article-159936.r15">[15]</xref> The distribution of 5-HT(1B) receptors encompasses the meningeal and coronary arteries, whereas 5-HT(1D) receptors are predominantly located on the presynaptic endings of the trigeminal nerve. Consequently, 5-HT(1B) receptor agonism leads to vasoconstriction in the coronary, cerebral, and peripheral arteries. On the other hand, 5-HT(1D) receptor agonism inhibits vascular inflammation in the dura mater and neuropeptide release from trigeminal nerve terminals.<xref ref-type="bibr" rid="article-159936.r16">[16]</xref><xref ref-type="bibr" rid="article-159936.r13">[13]</xref>&#x000a0;The dual effect of 5-HT(1B/1D) receptor agonism results in a decrease in perceived pain during an acute migraine attack.</p>
        <p>The activation of the trigeminovascular system is believed to underlie the majority of the pathophysiology of migraine pain. This includes processes such as plasma extravasation, vasodilation, heightened nociceptive transmission (via the release of neuropeptides like calcitonin gene-related peptide and adenylate cyclase-activating protein), and activation of mast cells. Activation of the trigeminovascular system is also responsible for the classic migraine characteristics, manifesting as the pulsating nature of pain and the unilateral, anterior, and periorbital distribution.<xref ref-type="bibr" rid="article-159936.r13">[13]</xref></p>
        <p>The interaction of eletriptan with 5-HT1B and 5-HT1D receptors by eletriptan initiates a cascade of intracellular events. Activation of 5-HT(1B/1D) receptors leads to the inhibition of adenylate cyclase activity through the G&#x003b1;i protein subunit, resulting in diminished cAMP levels.<xref ref-type="bibr" rid="article-159936.r17">[17]</xref>&#x000a0;This reduction in cAMP levels subsequently mitigates the activation of protein kinase A, which reduces the phosphorylation of essential proteins involved in neuronal excitation and sensitization. Furthermore, the activation of G-protein&#x02013;coupled inwardly rectifying potassium (GIRK) channels by G&#x003b2;&#x003b3; subunits, liberated upon G-protein&#x02013;coupled receptor (GPCR) activation, induces neuronal hyperpolarization. This hyperpolarization actively suppresses neuronal firing and curtails neurotransmitter release, thereby contributing to an overall reduction in neurogenic inflammation. Although there is evidence suggesting eletriptan's affinity for 5-HT(1A), 5-HT(1F), 5-HT(2E), and 5-HT(7) receptors, no identified clinical effects are linked to the involvement of these receptors.<xref ref-type="bibr" rid="article-159936.r1">[1]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Following&#x000a0;oral administration, eletriptan undergoes rapid absorption from the gastrointestinal tract, with peak plasma concentration (Tmax) typically occurring around 1.5 and 2 hours. The median time to reach peak plasma levels is 2 to 4 hours. Eletriptan exhibits an absolute bioavailability of approximately 50%. Administration with a high-fat meal increases the peak concentration (Cmax) and area under the curve (AUC) of eletriptan by about 20% to 30%.</p>
        <p><bold>Distribution:&#x000a0;</bold>Eletriptan has a volume of distribution of 138 L, and its plasma protein binding is moderate, accounting for approximately 85%.<xref ref-type="bibr" rid="article-159936.r7">[7]</xref></p>
        <p><bold>Metabolism:</bold> Eletriptan undergoes extensive metabolism primarily in the liver, predominantly by the cytochrome P450 3A4 (CYP3A4) enzyme.<xref ref-type="bibr" rid="article-159936.r18">[18]</xref>&#x000a0;The sole active metabolite is the <italic toggle="yes">N</italic>-demethylated form of eletriptan, exhibiting approximately 10% of the potency of the parent compound. Other minor metabolites include the <italic toggle="yes">N</italic>-oxide, the indole acetic acid derivative, and their glucuronides.</p>
        <p><bold>Elimination:</bold>&#x000a0;Eletriptan and its metabolites undergo elimination primarily through urine and feces. In the general population, eletriptan has a mean terminal elimination half-life of approximately 4 hours, whereas in the geriatric population, the half-life ranges between 4.4 and 5.7 hours.<xref ref-type="bibr" rid="article-159936.r19">[19]</xref>&#x000a0;The non-renal pathway contributes 90% of the overall clearance, with renal clearance contributing only 10%.<xref ref-type="bibr" rid="article-159936.r20">[20]</xref></p>
      </sec>
      <sec id="article-159936.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Currently, eletriptan is exclusively available in oral tablet form, distinguishing it from other drugs in the triptan class, which come in various formulations such as nasal sprays, oral tablets, oral disintegrating tablets, and subcutaneous injections.<xref ref-type="bibr" rid="article-159936.r21">[21]</xref><xref ref-type="bibr" rid="article-159936.r22">[22]</xref><xref ref-type="bibr" rid="article-159936.r23">[23]</xref> Ongoing exploration is underway to develop alternative formulations of eletriptan.<xref ref-type="bibr" rid="article-159936.r24">[24]</xref><xref ref-type="bibr" rid="article-159936.r25">[25]</xref></p>
        <p>Eletriptan was formulated as an oral tablet and is offered in 2 strengths&#x02014;20 mg and 40 mg.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Eletriptan is administered orally and is characterized by high lipophilicity.<xref ref-type="bibr" rid="article-159936.r26">[26]</xref> The recommended doses are 20 mg or 40 mg, with a preference for a single dose of 40 mg due to enhanced efficacy.<xref ref-type="bibr" rid="article-159936.r27">[27]</xref> If the initial dose of eletriptan proves ineffective, a second dose can be taken within 12 to 24 hours of the first dose, with a maximum recommended dose of 80 mg within a 24-hour period.<xref ref-type="bibr" rid="article-159936.r28">[28]</xref>&#x000a0;Similar to all other triptans, eletriptan should not be used more than twice weekly.<xref ref-type="bibr" rid="article-159936.r29">[29]</xref>&#x000a0;</p>
        <p>The development of central sensitization, involving the sensitization of neurons in the brain's ascending trigeminal pathways, can notably influence the efficacy of triptan therapy.<xref ref-type="bibr" rid="article-159936.r14">[14]</xref><xref ref-type="bibr" rid="article-159936.r30">[30]</xref>&#x000a0;Therefore, patients&#x000a0;are instructed to take eletriptan at the onset of the migraine attack, especially during the headache phase in individuals with aura, as eletriptan proves ineffective if taken during the aura phase and before the onset of the headache.<xref ref-type="bibr" rid="article-159936.r31">[31]</xref>&#x000a0;Efficacy data show eletriptan's superiority over other triptans at both 2 and 24 hours after administration.<xref ref-type="bibr" rid="article-159936.r19">[19]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;No dosage adjustment of eletriptan is necessary for mild-to-moderate hepatic impairment. However, the use of eletriptan is not recommended for individuals with severe hepatic impairment. Eletriptan undergoes extensive metabolism mediated by the liver enzyme CYP3A4, and its clearance may be diminished in individuals with hepatic impairment. Some experts recommend considering a lower dose of 20 mg for patients with moderate hepatic impairment.<xref ref-type="bibr" rid="article-159936.r32">[32]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;Eletriptan does not appear to be significantly affected by renal function, and no dosage adjustment of eletriptan is recommended for patients with mild, moderate, or severe renal impairment. However, as patients with renal impairment may have an increased risk of hypertension, it is advisable to monitor their blood pressure levels after the administration of eletriptan.</p>
        <p><bold>Pregnancy considerations:</bold> Triptans are not the preferred first-line treatment for pregnant patients with migraines.<xref ref-type="bibr" rid="article-159936.r33">[33]</xref>&#x000a0;Limited data exist on the safety and efficacy of eletriptan in pregnant women. Animal studies have shown some evidence of developmental toxicity at high doses. Eletriptan is categorized as an FDA pregnancy category C and category B1 drug by the Australian Therapeutic Goods Administration (TGA), indicating that there might be situations where the potential benefits outweigh the potential risks. However, most guidelines recommend avoiding the use of eletriptan during pregnancy unless deemed necessary.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Eletriptan is excreted into human milk in small amounts, and the concentration of its active metabolite is unknown. The relative infant dose of eletriptan is significantly lower than the maternal dose, estimated to be less than 1%, making it unlikely to cause adverse effects in breastfed infants.<xref ref-type="bibr" rid="article-159936.r34">[34]</xref>&#x000a0;To minimize infant exposure, it is advisable to avoid breastfeeding for 24 hours after taking eletriptan.</p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Eletriptan has not been studied in children younger than 18, and thus, it is&#x000a0;not approved for use in pediatric patients due to a lack of safety and efficacy studies in this population.<xref ref-type="bibr" rid="article-159936.r4">[4]</xref>&#x000a0;According to AHS guidelines, no evidence suggests that administering eletriptan OT 40 mg to adolescents increases the likelihood of experiencing headache pain response after 2 hours compared to those who receive a placebo. Notably, the FDA has approved almotriptan, rizatriptan, and zolmitriptan for treating migraines in individuals aged 12 to 17.<xref ref-type="bibr" rid="article-159936.r35">[35]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;Eletriptan has not demonstrated geriatric-specific issues limiting its use in older patients.<xref ref-type="bibr" rid="article-159936.r1">[1]</xref>&#x000a0;However, caution may be warranted in older individuals due to a potentially higher prevalence of cardiovascular risk factors and age-related kidney disorders.</p>
      </sec>
      <sec id="article-159936.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse events reported from eletriptan use are mostly mild, moderate, and transient.<xref ref-type="bibr" rid="article-159936.r36">[36]</xref>&#x000a0;Although eletriptan is associated with nausea, dizziness, drowsiness, and coronary vasoconstriction, the most common adverse effects include a group of sensations referred to as "triptan sensations," including paresthesia, flushing, tingling, chest tightness, and neck pain.<xref ref-type="bibr" rid="article-159936.r37">[37]</xref>&#x000a0;Additional effects, such as palpitations, headaches, chills, pain, hypertonia, hypoesthesia, diaphoresis, abdominal pain, including cramps, discomfort, and pressure, xerostomia, dysphagia, dyspepsia, pharyngitis, back pain, and generalized weakness, have been reported, albeit at a much lower incidence ranging from 1% to 7%.<xref ref-type="bibr" rid="article-159936.r32">[32]</xref>&#x000a0;</p>
        <p>In the evaluation of adverse events, it is crucial to highlight that anaphylaxis, anaphylactoid, and hypersensitivity reactions have occurred, albeit at a rate of less than 1%, and may pose a life-threatening or fatal risk.<xref ref-type="bibr" rid="article-159936.r38">[38]</xref>&#x000a0;In addition, 5-HT(1B/1D) agonist administration has been associated with transient cardiac ischemia, coronary artery vasospasm, myocardial infarction, cardiac arrest, ventricular tachycardia or fibrillation, stroke, hypertensive crises, vasospasm-related events, and death. As reported, serotonin syndrome is an adverse effect of eletriptan. Therefore, it is not recommended to use certain drugs that enhance the serotonergic effect of eletriptan concurrently. Clinical signs of serotonin syndrome include clonus, hyperreflexia, diaphoresis, altered mental status, tremor, autonomic instability, and hyperthermia.<xref ref-type="bibr" rid="article-159936.r39">[39]</xref>&#x000a0;</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>As eletriptan is a primary substrate of the CYP3A4 enzyme, it is advised not to administer eletriptan within at least 72 hours of a potent CYP3A4 inhibitor.<xref ref-type="bibr" rid="article-159936.r40">[40]</xref> Furthermore, eletriptan may interact with oral contraceptives due to its CYP3A4 metabolism.<xref ref-type="bibr" rid="article-159936.r29">[29]</xref> Eletriptan should not be coadministered with monoamine oxidase inhibitors, other triptans (5-HT1D receptor agonists), or nefazodone due to the high risk of an increased serotonergic effect, which could&#x000a0;lead to serotonin syndrome. Although serotonergic agonists may be utilized concurrently with eletriptan therapy, close monitoring for signs and symptoms of serotonin syndrome is recommended, especially during initiation and dose increases.<xref ref-type="bibr" rid="article-159936.r7">[7]</xref></p>
      </sec>
      <sec id="article-159936.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Eletriptan is contraindicated in patients with conditions such as coronary artery vasospasm, ischemic coronary artery disease, uncontrolled hypertension, peripheral vascular disease, and ischemic bowel disease.<xref ref-type="bibr" rid="article-159936.r41">[41]</xref>&#x000a0;Additional cardiovascular contraindications include Wolff-Parkinson-White syndrome or cardiac accessory conduction pathway disorders.<xref ref-type="bibr" rid="article-159936.r42">[42]</xref>&#x000a0;</p>
        <p>Eletriptan is metabolized by CYP3A4 enzymes and is contraindicated within 72 hours of recent use of potent CYP3A4 inhibitors.<xref ref-type="bibr" rid="article-159936.r43">[43]</xref>&#x000a0;Furthermore, eletriptan is also contraindicated if another 5-HT(1) agonist, ergotamine-containing, or ergot-type medication has been taken within the last 72 hours due to the risk of serotonin syndrome.<xref ref-type="bibr" rid="article-159936.r32">[32]</xref> Eletriptan should be avoided in individuals with hypersensitivity reactions to prevent potential allergic responses, such as angioedema, anaphylaxis, rash, itching, swelling, or breathing difficulties. According to the FDA label, eletriptan is contraindicated in basilar or hemiplegic migraines. However, recent evidence suggests the safety of triptans in basilar migraines.<xref ref-type="bibr" rid="article-159936.r44">[44]</xref><xref ref-type="bibr" rid="article-159936.r45">[45]</xref>&#x000a0;</p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>The FDA has not issued any box warnings related to eletriptan at present.</p>
        <p>
<bold>Precautions</bold>
</p>
        <p>Eletriptan use is associated with a risk of serotonin syndrome or vasospastic episodes, particularly when used concomitantly with other drugs. This risk is heightened in the geriatric population or patients with severe hepatic impairment,&#x000a0;which may exacerbate underlying cardiovascular conditions.<xref ref-type="bibr" rid="article-159936.r41">[41]</xref> Thus, meticulous monitoring of cardiac function, electrocardiogram (ECG), and blood pressure is vital when prescribing eletriptan, especially for patients with known cardiac comorbidities.<bold>&#x000a0;</bold>Immediate discontinuation of eletriptan is necessary in the case of subarachnoid hemorrhage.<xref ref-type="bibr" rid="article-159936.r46">[46]</xref></p>
      </sec>
      <sec id="article-159936.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients should be monitored for any adverse effects listed in the Adverse Effects section. In addition, clinicians should assess the response to eletriptan therapy, evaluate migraine recurrence, and observe consistent responses to eletriptan. Clinicians should also assess the patient's ability to function during a migraine attack by evaluating additional common migraine symptoms such as nausea, vomiting, photophobia, and phonophobia.<xref ref-type="bibr" rid="article-159936.r18">[18]</xref>&#x000a0;Furthermore, clinicians can monitor response to therapy by using validated scores such as the visual analog scale and pain intensity scale.<xref ref-type="bibr" rid="article-159936.r47">[47]</xref></p>
      </sec>
      <sec id="article-159936.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>The most prevalent signs and symptoms of eletriptan overdose align with those of other triptans, including chest pain or tightness, jaw or neck pain or tightness, shortness of breath, palpitations, dizziness, nausea, vomiting, and sweating.<xref ref-type="bibr" rid="article-159936.r32">[32]</xref>&#x000a0;These symptoms may indicate severe cardiovascular complications, such as myocardial ischemia due to coronary vasospasm, arrhythmia, or hypertensive crisis or emergency. Non-ST-elevation myocardial infarction (NSTEMI) due to eletriptan overdose has been reported.<xref ref-type="bibr" rid="article-159936.r48">[48]</xref></p>
        <p>Other possible signs and symptoms of eletriptan overdose include headache, confusion, agitation, hallucinations, seizures, coma, stroke, cerebral hemorrhage or ischemia, peripheral vascular ischemia or infarction, gastrointestinal ischemia or infarction, renal failure, liver failure, and death.</p>
        <p>Eletriptan overdose can also induce serotonin syndrome, a rare but potentially fatal condition arising from an excess of serotonin in the body. Serotonin syndrome can be triggered by the concurrent use of eletriptan with other medications that elevate serotonin levels, including antidepressants, opioids, or other triptans. The symptoms of serotonin syndrome include restlessness, agitation, confusion, hallucinations, fever, sweating, shivering, muscle stiffness or twitching, tremors, ataxia, nausea, vomiting, diarrhea, and arrhythmias.&#x000a0;National Poison Data System data analysis indicates a low risk of severe effects or death resulting from triptan toxicity. Triptan toxidrome is characterized by tachycardia, hypertension, and drowsiness. The study also identifies a higher risk of mortality associated with advanced age and simultaneous use of benzodiazepines or tricyclic antidepressants.<xref ref-type="bibr" rid="article-159936.r49">[49]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Although a specific antidote for triptan toxicity does not exist, it is recommended to discontinue eletriptan&#x000a0;therapy and initiate cyproheptadine therapy, if toxicity is suspected, particularly in the case of serotonin syndrome. Notably, eletriptan toxicity is associated with a low risk of death.<xref ref-type="bibr" rid="article-159936.r49">[49]</xref> In managing eletriptan toxicity, the primary approaches involve decontamination, supportive care, airway management, monitoring patient vitals, and consulting with a medical toxicologist in cases of significant overdose. Due to the large volume of drug distribution, hemodialysis is unlikely to be effective.</p>
      </sec>
      <sec id="article-159936.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Migraines are incapacitating headaches that can persist&#x000a0;for up to 72 hours if left untreated or treated inadequately. Patients commonly encounter accompanying symptoms such as nausea and vomiting, photophobia, and phonophobia, all of which can significantly impact the individual's daily functioning. Therefore, although the treatment of migraines is multifactorial, it is essential.<xref ref-type="bibr" rid="article-159936.r50">[50]</xref></p>
        <p>Quality patient education is integral to the success of migraine management plans. Patients should be informed about common migraine triggers, such as skipped meals, poor sleep, stress, alcohol, menstruation, and specific types of food. Furthermore, patients should be empowered to identify their triggers for more personalized care.<xref ref-type="bibr" rid="article-159936.r51">[51]</xref>&#x000a0;Although patients should be advised to avoid any unidentified triggers, it is recognized that, often, triggers cannot be entirely avoided. Therefore, pharmacological management also assumes a crucial role in migraine management. Depending on the severity and frequency of the patient's migraines, a healthcare provider may prescribe a pharmacological agent for migraine prophylaxis. Abortive pharmacological therapies, such as triptans, are recommended for use at the onset of a migraine attack.</p>
        <p>The interprofessional healthcare team must offer counseling to patients regarding triptan use, emphasizing that eletriptan should be taken at the onset of the migraine attack and not during the aura alone to achieve the most effective results. If eletriptan fails to provide the desired relief for a patient's migraines, the healthcare team should contemplate alternative triptans or other abortive agents. Patients should be informed about potential adverse effects and instructed to seek emergency medical treatment if severe adverse effects are suspected, such as chest pain, pressure or tightness, palpitations, altered mental status, new onset of neurological deficits, symptoms of anaphylaxis, or serotonin syndrome.</p>
        <p>Healthcare providers should be vigilant for signs and symptoms of serotonin syndrome in patients concurrently using eletriptan with a&#x000a0;selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) despite the low risk of serotonin syndrome.<xref ref-type="bibr" rid="article-159936.r52">[52]</xref> Patients should be informed about the risk of developing eletriptan overuse headaches, defined as taking eletriptan for 10 or more days in a month. Those who require eletriptan for 10 or more days per month are suitable candidates for prophylactic migraine therapy.<xref ref-type="bibr" rid="article-159936.r53">[53]</xref></p>
        <p>Eletriptan is an effective abortive medication for the management of migraines. An evidence-based approach is crucial for managing migraines, necessitating the reassessment of the efficacy of any prophylactic or abortive pharmacological agent. Effectively managing migraines demands collaborative efforts and high-quality communication among interprofessional healthcare team members. Care coordination is vital in ensuring the patient's migraine management therapy is individualized, well-managed, and in the patient's best interest.&#x000a0;The healthcare team, including clinicians (MDs, DOs, NPs, and PAs), neurologists or headache specialists, nurses, and pharmacists, should work together to deliver effective, patient-centered care. This collaborative approach aims to minimize adverse events associated with eletriptan and maximize patient safety.</p>
      </sec>
      <sec id="article-159936.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159936&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159936">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159936/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159936">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159936.s10">
        <title>References</title>
        <ref id="article-159936.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strijbos</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Fugelli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Eletriptan Pfizer.</article-title>
            <source>Curr Opin Investig Drugs</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>9</issue>
            <fpage>1359</fpage>
            <page-range>1359-68</page-range>
            <pub-id pub-id-type="pmid">12498013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Napier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Melrose</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McHarg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wallis</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.</article-title>
            <source>Eur J Pharmacol</source>
            <year>1999</year>
            <month>Mar</month>
            <day>05</day>
            <volume>368</volume>
            <issue>2-3</issue>
            <fpage>259</fpage>
            <page-range>259-68</page-range>
            <pub-id pub-id-type="pmid">10193663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <article-title>Drugs for migraine.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2023</year>
            <month>Jun</month>
            <day>12</day>
            <volume>65</volume>
            <issue>1678</issue>
            <fpage>89</fpage>
            <page-range>89-96</page-range>
            <pub-id pub-id-type="pmid">37266987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eiland</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>The use of triptans for pediatric migraines.</article-title>
            <source>Paediatr Drugs</source>
            <year>2010</year>
            <month>Dec</month>
            <day>01</day>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>379</fpage>
            <page-range>379-89</page-range>
            <pub-id pub-id-type="pmid">21028917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cameron</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kotb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coyle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Skidmore</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>55 Suppl 4</volume>
            <fpage>221</fpage>
            <page-range>221-35</page-range>
            <pub-id pub-id-type="pmid">26178694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sandrini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perrotta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tassorelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Eletriptan.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>1587</fpage>
            <page-range>1587-98</page-range>
            <pub-id pub-id-type="pmid">19929447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Curto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lionetto</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Andr&#x000e9;s</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Negro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martelletti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>414</fpage>
            <page-range>414-23</page-range>
            <pub-id pub-id-type="pmid">27582896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Valade</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Almas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hettiarachchi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sikes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of eletriptan in triptan-na&#x000ef;ve patients: results of a combined analysis.</article-title>
            <source>Headache</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-8</page-range>
            <pub-id pub-id-type="pmid">17300357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marmura</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-20</page-range>
            <pub-id pub-id-type="pmid">25600718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zebenholzer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>W&#x000f6;ber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vigl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wessely</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Eletriptan for the short-term prophylaxis of cluster headache.</article-title>
            <source>Headache</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>361</fpage>
            <page-range>361-4</page-range>
            <pub-id pub-id-type="pmid">15109360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>GY</given-names>
              </name>
              <collab>Treatment Guidelines Subcommittee of the Taiwan Headache Society</collab>
            </person-group>
            <article-title>2022 Taiwan Guidelines for Acute and Preventive Treatment of Cluster Headaches.</article-title>
            <source>Acta Neurol Taiwan</source>
            <year>2022</year>
            <month>Dec</month>
            <day>30</day>
            <volume>31(4)</volume>
            <fpage>254</fpage>
            <page-range>254-273</page-range>
            <pub-id pub-id-type="pmid">37431108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Recober</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of Migraine.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2021</year>
            <month>Jun</month>
            <day>01</day>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>586</fpage>
            <page-range>586-596</page-range>
            <pub-id pub-id-type="pmid">34048393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbanti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Egeo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mitsikostas</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?</article-title>
            <source>Headache</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>59</volume>
            <issue>9</issue>
            <fpage>1659</fpage>
            <page-range>1659-1661</page-range>
            <pub-id pub-id-type="pmid">31508812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Migraine pathophysiology and its clinical implications.</article-title>
            <source>Cephalalgia</source>
            <year>2004</year>
            <volume>24 Suppl 2</volume>
            <fpage>2</fpage>
            <page-range>2-7</page-range>
            <pub-id pub-id-type="pmid">15595988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gawel</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Grujich</surname>
                <given-names>NN</given-names>
              </name>
            </person-group>
            <article-title>Eletriptan.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>1869</fpage>
            <page-range>1869-74</page-range>
            <pub-id pub-id-type="pmid">11772292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takiya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Piccininni</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Kamath</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of eletriptan in the treatment of acute migraine.</article-title>
            <source>Pharmacotherapy</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-28</page-range>
            <pub-id pub-id-type="pmid">16506353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sheftell</surname>
                <given-names>FD</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of the 5-HT1B/1D receptor agonists.</article-title>
            <source>Arch Neurol</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>59</volume>
            <issue>7</issue>
            <fpage>1084</fpage>
            <page-range>1084-8</page-range>
            <pub-id pub-id-type="pmid">12117355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belv&#x000ed;s</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pagonabarraga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kulisevsky</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Individual triptan selection in migraine attack therapy.</article-title>
            <source>Recent Pat CNS Drug Discov</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-81</page-range>
            <pub-id pub-id-type="pmid">19149716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinclair</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sturrock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Matharu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Headache management: pharmacological approaches.</article-title>
            <source>Pract Neurol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>411</fpage>
            <page-range>411-23</page-range>
            <pub-id pub-id-type="pmid">26141299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Alderman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>331</fpage>
            <page-range>331-337</page-range>
            <pub-id pub-id-type="pmid">29497279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>75</volume>
            <issue>10</issue>
            <fpage>1369</fpage>
            <page-range>1369-1378</page-range>
            <pub-id pub-id-type="pmid">31446449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cady</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan: update and review.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>1503</fpage>
            <page-range>1503-14</page-range>
            <pub-id pub-id-type="pmid">16859433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antonaci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ghiotto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in migraine therapy.</article-title>
            <source>Springerplus</source>
            <year>2016</year>
            <volume>5</volume>
            <fpage>637</fpage>
            <pub-id pub-id-type="pmid">27330903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siddique</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zaman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarfraz</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Butt</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Fassih</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Albadrani</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bayram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alfaifi</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Abdel-Daim</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>The Development of Eletriptan Hydrobromide Immediate Release Buccal Films Using Central Composite Rotatable Design: An In Vivo and In Vitro Approach.</article-title>
            <source>Polymers (Basel)</source>
            <year>2022</year>
            <month>Sep</month>
            <day>23</day>
            <volume>14</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">36235932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Doko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sultana</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eskandari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prgomet</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Feiler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>R&#x000f6;nn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dahlstr&#x000f6;m</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Engblom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rklund</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Oral transmucosal delivery of eletriptan for neurological diseases.</article-title>
            <source>Int J Pharm</source>
            <year>2022</year>
            <month>Nov</month>
            <day>05</day>
            <volume>627</volume>
            <fpage>122222</fpage>
            <pub-id pub-id-type="pmid">36155795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormack</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Spotlight on eletriptan in migraine.</article-title>
            <source>CNS Drugs</source>
            <year>2006</year>
            <volume>20</volume>
            <issue>11</issue>
            <fpage>961</fpage>
            <page-range>961-4</page-range>
            <pub-id pub-id-type="pmid">17044732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Worthington</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gawel</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gladstone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dilli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aube</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leroux</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
              <collab>Canadian Headache Society Acute Migraine Treatment Guideline Development Group</collab>
            </person-group>
            <article-title>Canadian Headache Society Guideline: acute drug therapy for migraine headache.</article-title>
            <source>Can J Neurol Sci</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>5 Suppl 3</issue>
            <fpage>S1</fpage>
            <page-range>S1-S80</page-range>
            <pub-id pub-id-type="pmid">23968886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia-Ramos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>MacGregor</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bordini</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Leston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hettiarachchi</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.</article-title>
            <source>Cephalalgia</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>869</fpage>
            <page-range>869-76</page-range>
            <pub-id pub-id-type="pmid">14616928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Nicolas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nicolas</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Triptans</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">32119394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Microglial NLRP3 inflammasome activation mediates IL-1&#x003b2; release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model.</article-title>
            <source>J Neuroinflammation</source>
            <year>2019</year>
            <month>Apr</month>
            <day>10</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>78</fpage>
            <pub-id pub-id-type="pmid">30971286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olesen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hettiarachchi</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>No effect of eletriptan administration during the aura phase of migraine.</article-title>
            <source>Eur J Neurol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>671</fpage>
            <page-range>671-7</page-range>
            <pub-id pub-id-type="pmid">15469451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormack</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Eletriptan: a review of its use in the acute treatment of migraine.</article-title>
            <source>Drugs</source>
            <year>2006</year>
            <volume>66</volume>
            <issue>8</issue>
            <fpage>1129</fpage>
            <page-range>1129-49</page-range>
            <pub-id pub-id-type="pmid">16789799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <article-title>Headaches in Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 3.</article-title>
            <source>Obstet Gynecol</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>139</volume>
            <issue>5</issue>
            <fpage>944</fpage>
            <page-range>944-972</page-range>
            <pub-id pub-id-type="pmid">35576364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <chapter-title>Eletriptan</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>5</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30000275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Billinghurst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Linsdell</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vandermeer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Crumley</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Durec</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Klassen</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Hartling</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Drugs for the acute treatment of migraine in children and adolescents.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Apr</month>
            <day>19</day>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>CD005220</fpage>
            <pub-id pub-id-type="pmid">27091010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheftell</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pitman</surname>
                <given-names>V</given-names>
              </name>
              <collab>Eletriptan Steering Committee</collab>
            </person-group>
            <article-title>Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States.</article-title>
            <source>Headache</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>202</fpage>
            <page-range>202-13</page-range>
            <pub-id pub-id-type="pmid">12603638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-Hern&#x000e1;ndez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marichal-Cancino</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>MaassenVanDenBrink</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Villal&#x000f3;n</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Side effects associated with current and prospective antimigraine pharmacotherapies.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-41</page-range>
            <pub-id pub-id-type="pmid">29226741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorlund</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Toor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Druyts</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bhambri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Donnet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Comparative tolerability of treatments for acute migraine: A network meta-analysis.</article-title>
            <source>Cephalalgia</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>965</fpage>
            <page-range>965-978</page-range>
            <pub-id pub-id-type="pmid">27521843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Millson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Safety profile of the triptans.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-32</page-range>
            <pub-id pub-id-type="pmid">12904112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Modi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Soni</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dobaria</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Srinivas</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes.</article-title>
            <source>Xenobiotica</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>49</volume>
            <issue>10</issue>
            <fpage>1202</fpage>
            <page-range>1202-1208</page-range>
            <pub-id pub-id-type="pmid">30588869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ailani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>MS</given-names>
              </name>
              <collab>Board of Directors of the American Headache Society</collab>
            </person-group>
            <article-title>The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.</article-title>
            <source>Headache</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>61</volume>
            <issue>7</issue>
            <fpage>1021</fpage>
            <page-range>1021-1039</page-range>
            <pub-id pub-id-type="pmid">34160823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Shewale</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Pavlovic</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Doshi</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data.</article-title>
            <source>J Prim Care Community Health</source>
            <year>2020</year>
            <season>Jan-Dec</season>
            <volume>11</volume>
            <fpage>2150132720963680</fpage>
            <pub-id pub-id-type="pmid">33095099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tepper</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boccuzzi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.</article-title>
            <source>Headache</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-8</page-range>
            <pub-id pub-id-type="pmid">12864757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vgontzas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Episodic Migraine With and Without Aura: Key Differences and Implications for Pathophysiology, Management, and Assessing Risks.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <day>05</day>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>78</fpage>
            <pub-id pub-id-type="pmid">30291554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CX</given-names>
              </name>
            </person-group>
            <article-title>Migraine with Brainstem Aura Accompanied by Disorders of Consciousness.</article-title>
            <source>J Pain Res</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>1119</fpage>
            <page-range>1119-1127</page-range>
            <pub-id pub-id-type="pmid">33907459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshioka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ryujin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A pediatric case of reversible cerebral vasoconstriction syndrome with cortical subarachnoid hemorrhage.</article-title>
            <source>Brain Dev</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>796</fpage>
            <page-range>796-8</page-range>
            <pub-id pub-id-type="pmid">22285527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanderPluym</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Halker Singh</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Urtecho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Nayfeh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Torres Roldan</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Farah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saadi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abd-Rabu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Daraz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prokop</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Jun</month>
            <day>15</day>
            <volume>325</volume>
            <issue>23</issue>
            <fpage>2357</fpage>
            <page-range>2357-2369</page-range>
            <pub-id pub-id-type="pmid">34128998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hebert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mercedes</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Myocardial infarction after taking eletriptan.</article-title>
            <source>Rev Port Cardiol</source>
            <year>2014</year>
            <season>Jul-Aug</season>
            <volume>33</volume>
            <issue>7-8</issue>
            <fpage>475.e1</fpage>
            <page-range>475.e1-3</page-range>
            <pub-id pub-id-type="pmid">25155004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robblee</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Butterfield</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Triptan and ergotamine overdoses in the United States: Analysis of the National Poison Data System.</article-title>
            <source>Neurology</source>
            <year>2020</year>
            <month>Apr</month>
            <day>07</day>
            <volume>94</volume>
            <issue>14</issue>
            <fpage>e1460</fpage>
            <page-range>e1460-e1469</page-range>
            <pub-id pub-id-type="pmid">31792093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boisselle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guthmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cable</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical inquiry. What clinical clues differentiate migraine from sinus headaches? Pulsatile quality, duration of 4 to 72 hours, unilateral location, nausea or vomiting, and disabling intensity.</article-title>
            <source>J Fam Pract</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>62</volume>
            <issue>12</issue>
            <fpage>752</fpage>
            <page-range>752-4</page-range>
            <pub-id pub-id-type="pmid">24340338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marmura</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Triggers, Protectors, and Predictors in Episodic Migraine.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <day>05</day>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>81</fpage>
            <pub-id pub-id-type="pmid">30291562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Sun-Edelstein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tietjen</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.</article-title>
            <source>Headache</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>1089</fpage>
            <page-range>1089-99</page-range>
            <pub-id pub-id-type="pmid">20618823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159936.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Holle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dresler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gaul</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Chronic Headache Due to Overuse of Analgesics and Anti-Migraine Agents.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>115</volume>
            <issue>22</issue>
            <fpage>365</fpage>
            <page-range>365-370</page-range>
            <pub-id pub-id-type="pmid">29932046</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
